A subcutaneous version of Bristol-Myers Squibb's Orencia, a treatment for rheumatoid arthritis, was approved by the FDA. The formulation is expected to be available next month.
Published in Brief:
|Vice President of Regulatory Affairs||
|Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX||
|Santa Clara, CA|
|Senior Director, Biostatistics||